BEAM THERAPY AND LONG-TERM HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
https://doi.org/10.17650/1726-9776-2011-7-2-73-77
Abstract
The authors describe their experience in treating patients with prostate cancer (PC). The data of 68 patients undergoing beam therapy in combination with long-term hormonal therapy are restrospectively analyzed. The patients mainly present with locally advanced tumors. Radiotherapy was performed with a cumulative focal dose of as high as 70 Gy; hormonal therapy involved orchiectomy or long-term adjuvant therapy with luteinizing hormone releasing-hormone analogues for 36 months. Five-year outcomes were estimated; relapse-free and biochemical progression-free survival rates were 88.9 ± 4.9 and 89.4 ± 5.3%, respectively. Early and late radiation damages were also evaluated: the rate of grades 2 and 3 acute radiation-induced urinary tract lesions was 64.3 and 3.6%, respectively; that of grades 1 and 2 gastrointestinal lesions was 26.8 and 7.1%; and that of grade 2 late lesions was not greater than 1.5%.
About the Authors
A. O. Karyakin
Medical Radiology Research Center, Ministry of Health and Social Development of Russia, Obninsk
Russian Federation
Russian Federation
V. B. Matveev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
T. V. Sviridova
Medical Radiology Research Center, Ministry of Health and Social Development of Russia, Obninsk
Russian Federation
Russian Federation
N. A. Gorban
Medical Radiology Research Center, Ministry of Health and Social Development of Russia, Obninsk
Russian Federation
Russian Federation
Yu. V. Gumenetskaya
Medical Radiology Research Center, Ministry of Health and Social Development of Russia, Obninsk
Russian Federation
Russian Federation
References
1. Чиссов В.И., Старинский В.В. Состояние онкологической помощи населению России в 2008 г. М., 2009.
2. Матвеев В.Б., Волкова М.И. Роль гормонотерапии у больных локализованным и местно-распространенным раком предстательной железы при использовании радикальных методов лечения. Онкоурология 2005;(2):54–8.
3. Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360(9327):103–6.
4. Bolla M., Collette L., Van Tienhoven G. et al. Ten year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy; a phase III EORTC study. Int Radiat Oncol Biol Phys 2008;72(1 Suppl 1):30–1.
5. Pilepich M.V., Winter K., Lawton C. et al. Phase trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proc Am Society Clin Oncol 2003;22;Abstr.1530.
6. Ray M.E., Thames H.D., Levy L.B. et al. PSA nadir predicts biochemical and distant failure after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006;64(4):1140–50.
7. Klein E.A. Management of prostate cancer. 2000; p.166–7.
Review
For citations:
Karyakin A.O., Matveev V.B., Sviridova T.V., Gorban N.A., Gumenetskaya Yu.V. BEAM THERAPY AND LONG-TERM HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER. Cancer Urology. 2011;7(2):73-77. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-2-73-77
Views:
1015
Email this article 